| Q57133480 | Q57133480 |
| Q37710823 | A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis |
| Q28076622 | A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients |
| Q37156735 | A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial |
| Q45327403 | Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis |
| Q38465754 | Adiponectin and its receptor signaling: an anti-cancer therapeutic target and its implications for anti-tumor immunity |
| Q39128628 | Adiponectin as a Potential Therapeutic Target for Prostate Cancer |
| Q39411380 | Adiponectin inhibits oxidative stress in human prostate carcinoma cells |
| Q92854261 | Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk |
| Q92419678 | Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis |
| Q33640049 | Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study |
| Q53230106 | Association of variants on ADIPOQ and AdipoR1 and the prognosis of gastric cancer patients after gastrectomy treatment. |
| Q43573789 | Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study |
| Q92622133 | Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study |
| Q24625223 | Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis |
| Q36386086 | Case-control study of markers of insulin resistance and endometrial cancer risk |
| Q26749399 | Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies |
| Q36979100 | Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer |
| Q41118011 | Development and Application of a Lifestyle Score for Prevention of Lethal Prostate Cancer |
| Q37577156 | Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer |
| Q33785535 | Exercise-induced biochemical changes and their potential influence on cancer: a scientific review |
| Q34131778 | Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival |
| Q34300064 | Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans |
| Q34536858 | Genetic variations of the ADIPOQgene and risk of prostate cancer in Chinese Han men. |
| Q51101393 | Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1. |
| Q85073284 | Impact of Body Mass Index on Outcomes After Conformal Radiotherapy in Patients With Prostate Cancer |
| Q47129584 | Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives. |
| Q34469869 | In prostate cancer, low adiponectin levels are not associated with insulin resistance. |
| Q34075580 | Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer |
| Q46493226 | Lack of adiponectin and adiponectin receptor 1 contributes to benign prostatic hyperplasia |
| Q27025735 | Lifestyle and dietary factors in the prevention of lethal prostate cancer |
| Q37103485 | Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link |
| Q34794028 | Metabolic imbalance and prostate cancer progression. |
| Q30234898 | Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences |
| Q36044730 | Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study |
| Q35222084 | New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK |
| Q36685022 | Obesity and prostate cancer: weighing the evidence |
| Q36810924 | Obesity, energy balance, and cancer: new opportunities for prevention |
| Q26864117 | Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue |
| Q47892728 | PPARGC1A and ADIPOQ polymorphisms are associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity |
| Q40515239 | Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms |
| Q47178567 | Periprostatic adipose inflammation is associated with high-grade prostate cancer. |
| Q33910774 | Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor |
| Q34157477 | Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study |
| Q47313462 | Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. |
| Q36135601 | Plasma Leptin Levels and Risk of Incident Cancer: Results from the Dallas Heart Study. |
| Q42699705 | Prostate cancer gene expression signature of patients with high body mass index |
| Q91830322 | Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis |
| Q36106260 | Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer |
| Q36421235 | Serum adiponectin level and different kinds of cancer: a review of recent evidence |
| Q34584928 | Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot study |
| Q51393972 | Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. |
| Q87498740 | Serum omentin level in patients with prostate cancer |
| Q36680139 | Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression |
| Q52725879 | The Epidemiology of Prostate Cancer. |
| Q26830203 | The balance between leptin and adiponectin in the control of carcinogenesis - focus on mammary tumorigenesis |
| Q33856172 | The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer |
| Q38096735 | The fat side of prostate cancer |
| Q34271986 | The role of adiponectin in cancer: a review of current evidence |
| Q58835433 | Tumor Cell-educated Periprostatic Adipose Tissue Acquires an Aggressive Cancer-promoting Secretory Profile |
| Q35784565 | Tumor expression of adiponectin receptor 2 and lethal prostate cancer |
| Q51377592 | Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men. |
| Q37685889 | Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. |
| Q40185822 | Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer |